Freenome (NASDAQ:FRNM – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.00.
A number of equities analysts have recently commented on the company. Leerink Partners initiated coverage on Freenome in a report on Friday, August 14th. They issued an “outperform” rating and a $18.00 target price for the company. Guggenheim initiated coverage on Freenome in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price target for the company. Weiss Ratings began coverage on shares of Freenome in a research note on Monday, August 24th. They set a “sell (d+)” rating for the company. TD Cowen started coverage on shares of Freenome in a research report on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, BTIG Research began coverage on shares of Freenome in a research note on Monday, August 17th. They issued a “buy” rating and a $17.00 target price on the stock.
Check Out Our Latest Analysis on FRNM
Freenome Trading Up 5.0%
Freenome Company Profile
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. Its approach combines artificial intelligence with multiomics analysis, examining biological signals in blood, including circulating tumor material and other molecular indicators.
The company has focused on noninvasive screening tests for colorectal cancer and other cancers. Freenome’s products remain in development and are being evaluated through clinical research and validation studies; the company’s tests are not described here as broadly approved diagnostic products.
Founded in 2014 and headquartered in the United States, Freenome has worked with healthcare providers, research organizations and pharmaceutical companies to advance its screening technology.
Featured Stories
- Five stocks we like better than Freenome
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
